Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
2014 · New England Journal of Medicine · 1,825 citations
https://doi.org/10.1056/nejmoa1406037
P
Paul Nathan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
469
Papers
30.2K
Citations
70
h-index
210
i10-index
Paul Nathan is an academic researcher from Mount Vernon Hospital. The author has contributed to research in topics: Melanoma and MAPK Pathways & Renal cell carcinoma treatment & Cancer Immunotherapy and Biomarkers. The author has an h-index of 70, co-authored 399 publications.
ORCID: 0000-0002-2327-3250Papers by this author
worksFive-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
2019 · New England Journal of Medicine · 1,316 citations
https://doi.org/10.1056/nejmoa1904059
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
2021 · New England Journal of Medicine · 828 citations
https://doi.org/10.1056/nejmoa2103485
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
2022 · Nature Medicine · 403 citations
https://doi.org/10.1038/s41591-022-01695-5
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
2022 · European Journal of Cancer · 310 citations
https://doi.org/10.1016/j.ejca.2022.03.008
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023
2023 · European Journal of Cancer · 236 citations
https://doi.org/10.1016/j.ejca.2023.113254
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat